Theravance Biopharma Inc
NASDAQ:TBPH

Watchlist Manager
Theravance Biopharma Inc Logo
Theravance Biopharma Inc
NASDAQ:TBPH
Watchlist
Price: 9.85 USD 0.61%
Market Cap: 484.3m USD
Have any thoughts about
Theravance Biopharma Inc?
Write Note

Theravance Biopharma Inc
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Theravance Biopharma Inc
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Theravance Biopharma Inc
NASDAQ:TBPH
Accounts Payable
$1.5m
CAGR 3-Years
-45%
CAGR 5-Years
-30%
CAGR 10-Years
-12%
No Stocks Found

Theravance Biopharma Inc
Glance View

Market Cap
484.4m USD
Industry
Pharmaceuticals

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. The company is headquartered in George Town, Grand Cayman and currently employs 158 full-time employees. The company went IPO on 2014-05-16. The firm develops transformational medicines to improve the lives of patients suffering from serious illnesses. The firm's research is focused in the areas of inflammation and immunology. The company applies organ-selective knowledge to biologically compelling targets to discover and develop medicines, which are designed to treat underserved localized diseases and to limit systemic exposure. The firm is developing lung-selective medicines to treat respiratory disease, including YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its revefenacin is a long-acting muscarinic antagonist (LAMA). Its programs also include Nezulcitinib, Ampreloxetine (TD-9855), Izencitinib, TD-5202 and TD-8236.

TBPH Intrinsic Value
7.15 USD
Overvaluation 27%
Intrinsic Value
Price

See Also

What is Theravance Biopharma Inc's Accounts Payable?
Accounts Payable
1.5m USD

Based on the financial report for Sep 30, 2024, Theravance Biopharma Inc's Accounts Payable amounts to 1.5m USD.

What is Theravance Biopharma Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
-12%

Over the last year, the Accounts Payable growth was -39%. The average annual Accounts Payable growth rates for Theravance Biopharma Inc have been -45% over the past three years , -30% over the past five years , and -12% over the past ten years .

Back to Top